JP2016518324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518324A5 JP2016518324A5 JP2016501372A JP2016501372A JP2016518324A5 JP 2016518324 A5 JP2016518324 A5 JP 2016518324A5 JP 2016501372 A JP2016501372 A JP 2016501372A JP 2016501372 A JP2016501372 A JP 2016501372A JP 2016518324 A5 JP2016518324 A5 JP 2016518324A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- aryl
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 6
- -1 substituted Chemical class 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000004171 alkoxy aryl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005325 aryloxy aryl group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- CMONQYKXNSYVBH-UHFFFAOYSA-N 3-[4-[bis(2-methylpropyl)amino]-3-[(3-methyl-1,2-oxazol-5-yl)carbamoylamino]phenyl]butanoic acid Chemical compound CC(C)CN(CC(C)C)C1=CC=C(C(C)CC(O)=O)C=C1NC(=O)NC1=CC(C)=NO1 CMONQYKXNSYVBH-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003106 haloaryl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787939P | 2013-03-15 | 2013-03-15 | |
| US61/787,939 | 2013-03-15 | ||
| PCT/US2014/023877 WO2014150646A1 (en) | 2013-03-15 | 2014-03-12 | Ido inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016518324A JP2016518324A (ja) | 2016-06-23 |
| JP2016518324A5 true JP2016518324A5 (enExample) | 2017-03-02 |
| JP6313415B2 JP6313415B2 (ja) | 2018-04-18 |
Family
ID=50391513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501372A Active JP6313415B2 (ja) | 2013-03-15 | 2014-03-12 | Ｉｄｏ阻害剤 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9624188B2 (enExample) |
| EP (1) | EP2970114B1 (enExample) |
| JP (1) | JP6313415B2 (enExample) |
| KR (1) | KR20150129010A (enExample) |
| CN (1) | CN105324362B (enExample) |
| AU (1) | AU2014235816B2 (enExample) |
| BR (1) | BR112015022462A8 (enExample) |
| CA (1) | CA2907178A1 (enExample) |
| EA (1) | EA028424B1 (enExample) |
| ES (1) | ES2733546T3 (enExample) |
| HK (1) | HK1220442A1 (enExample) |
| IL (1) | IL241321A0 (enExample) |
| MA (1) | MA38483A1 (enExample) |
| MX (1) | MX2015012056A (enExample) |
| PE (1) | PE20151594A1 (enExample) |
| PH (1) | PH12015502028A1 (enExample) |
| SG (1) | SG11201506920QA (enExample) |
| WO (1) | WO2014150646A1 (enExample) |
| ZA (1) | ZA201506796B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| HRP20180971T1 (hr) * | 2013-03-15 | 2018-08-10 | Bristol-Myers Squibb Company | Inhibitori indolamin 2,3-dioksigenaze (ido) |
| CN105473550B (zh) | 2013-07-01 | 2019-02-15 | 百时美施贵宝公司 | Ido抑制剂 |
| CA2917964A1 (en) * | 2013-07-11 | 2015-01-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| SG10202001019TA (en) | 2015-03-23 | 2020-04-29 | Jounce Therapeutics Inc | Antibodies to icos |
| CA2981584A1 (en) * | 2015-04-03 | 2016-10-06 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| CN107922353A (zh) * | 2015-06-26 | 2018-04-17 | 百时美施贵宝公司 | Ido抑制剂 |
| BR112018000903A2 (pt) | 2015-07-16 | 2018-09-11 | Biokine Therapeutics Ltd. | composições e métodos para o tratamento de câncer |
| EP3324958B1 (en) | 2015-07-24 | 2021-07-28 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| KR20180054827A (ko) * | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 인돌아민 2,3-디옥시게나제의 조절제 |
| JP6971239B2 (ja) * | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| WO2017070423A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| MX2018009633A (es) | 2016-02-09 | 2018-12-17 | Inventisbio Inc | Inhibidor de indoleamina-2,3-dioxigenasa (ido). |
| JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
| RU2741911C2 (ru) * | 2016-04-29 | 2021-01-29 | Иомет Фарма Лтд. | Новые замещенные соединения имидазопиридина в качестве ингибиторов индоламин-2,3-диоксигеназы и/или триптофан-2,3-диоксигеназы |
| BR112018072669A2 (pt) * | 2016-05-12 | 2019-02-19 | Glaxosmithkline Intellectual Property Development Limited | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratamento uma doença ou condição que se beneficiaria da inibição de ido1, e, uso de um composto ou sal |
| AR108586A1 (es) | 2016-06-10 | 2018-09-05 | Lilly Co Eli | Compuestos de 2,3-dihidro-1h-indol |
| WO2018036414A1 (zh) * | 2016-08-23 | 2018-03-01 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
| MA46649A (fr) | 2016-10-13 | 2019-08-21 | Juno Therapeutics Inc | Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane |
| KR20190088480A (ko) | 2016-11-02 | 2019-07-26 | 조운스 테라퓨틱스, 인크. | Pd-1에 대한 항체 및 그의 용도 |
| CA3042698A1 (en) | 2016-11-04 | 2018-05-11 | Aximmune, Inc. | Beta-alethine, immune modulators, and uses thereof |
| EP3558978A1 (en) | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| EP3694506B1 (en) | 2017-10-09 | 2023-08-02 | Merck Sharp & Dohme LLC | Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| WO2019126514A2 (en) | 2017-12-22 | 2019-06-27 | Jounce Therapeutics, Inc. | Antibodies for lilrb2 |
| EP3697423A4 (en) | 2018-01-05 | 2021-08-11 | Dicerna Pharmaceuticals, Inc. | REDUCED EXPRESSION OF BETA-CATENIN AND IDO TO POTENTIALIZE IMMUNOTHERAPY |
| US11447449B2 (en) * | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP2021523213A (ja) | 2018-05-14 | 2021-09-02 | ジャウンス セラピューティックス， インク．Ｊｏｕｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 癌を治療する方法 |
| EP3823604A4 (en) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE |
| WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020081905A1 (en) | 2018-10-18 | 2020-04-23 | Jounce Therapeutics, Inc | Methods for treating cancer |
| WO2020086802A1 (en) | 2018-10-24 | 2020-04-30 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| US20210355222A1 (en) | 2018-10-26 | 2021-11-18 | Jounce Therapeutics, Inc. | Methods of Treating Cancer |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| WO2021091960A1 (en) | 2019-11-05 | 2021-05-14 | Jounce Therapeutics, Inc. | Methods of treating cancer with anti-pd-1 antibodies |
| CN115135385B (zh) | 2019-11-12 | 2024-05-10 | 纳米医疗有限公司 | 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法 |
| WO2021102618A1 (en) | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| US20230089426A1 (en) | 2020-01-13 | 2023-03-23 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
| CN111153846B (zh) * | 2020-01-17 | 2021-08-31 | 中国药科大学 | 吡咯类化合物、其制备方法和药物组合物与用途 |
| MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447957A (en) * | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
| JP4618845B2 (ja) * | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体 |
| AU2002222573A1 (en) * | 2000-12-05 | 2002-06-18 | Kyorin Pharmaceutical Co. Ltd. | Substituted carboxylic acid derivatives |
| US7312214B2 (en) | 2002-05-10 | 2007-12-25 | Bristol-Myers Squibb Company | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors |
| US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| ES2340179T3 (es) * | 2004-05-12 | 2010-05-31 | Bristol-Myers Squibb Company | Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas. |
| CA2575764A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as cb1 antagonists |
| GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| CN102083429B (zh) * | 2008-04-24 | 2014-05-28 | 新联基因公司 | Ido抑制剂 |
| HRP20180971T1 (hr) | 2013-03-15 | 2018-08-10 | Bristol-Myers Squibb Company | Inhibitori indolamin 2,3-dioksigenaze (ido) |
-
2014
- 2014-03-12 HK HK16108593.6A patent/HK1220442A1/zh unknown
- 2014-03-12 WO PCT/US2014/023877 patent/WO2014150646A1/en not_active Ceased
- 2014-03-12 AU AU2014235816A patent/AU2014235816B2/en not_active Ceased
- 2014-03-12 JP JP2016501372A patent/JP6313415B2/ja active Active
- 2014-03-12 MX MX2015012056A patent/MX2015012056A/es unknown
- 2014-03-12 ES ES14714106T patent/ES2733546T3/es active Active
- 2014-03-12 BR BR112015022462A patent/BR112015022462A8/pt not_active Application Discontinuation
- 2014-03-12 SG SG11201506920QA patent/SG11201506920QA/en unknown
- 2014-03-12 MA MA38483A patent/MA38483A1/fr unknown
- 2014-03-12 US US14/775,976 patent/US9624188B2/en active Active
- 2014-03-12 CA CA2907178A patent/CA2907178A1/en not_active Abandoned
- 2014-03-12 CN CN201480028214.8A patent/CN105324362B/zh not_active Expired - Fee Related
- 2014-03-12 EA EA201591823A patent/EA028424B1/ru not_active IP Right Cessation
- 2014-03-12 KR KR1020157029305A patent/KR20150129010A/ko not_active Ceased
- 2014-03-12 EP EP14714106.3A patent/EP2970114B1/en active Active
- 2014-03-12 PE PE2015001950A patent/PE20151594A1/es not_active Application Discontinuation
-
2015
- 2015-09-08 IL IL241321A patent/IL241321A0/en unknown
- 2015-09-10 PH PH12015502028A patent/PH12015502028A1/en unknown
- 2015-09-14 ZA ZA2015/06796A patent/ZA201506796B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016518324A5 (enExample) | ||
| JP2016519653A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2018515438A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2013056930A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2015514056A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2016501221A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2009541223A5 (enExample) | ||
| RU2015151502A (ru) | Химические соединения | |
| JP2015511609A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2015509975A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| RU2013109132A (ru) | Химические соединения | |
| JP2014518544A5 (enExample) | ||
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения |